Botulinum toxin treatments of depression

• US 8,609,112 B2
• Filed: 02/01/2013
• Issued: 12/17/2013
• Est. Priority Date: 10/29/2003
• Status: Expired due to Fees

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: Blumenfeld, Andrew M., Turkel, Catherine C., Brin, Mitchell F.
• Primary Examiner(s): Emch, Gregory S
• Application Number:
  US13/757,431
• Publication Number:
  US 20130142776A1
• Time in Patent Office: 319 Days
• Field of Search: None
• US Class Current: 424/247.1
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00

Abstract

Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.

Claims

1. A method for treating depression comprising directly administering a botulinum toxin to one or more nerves of a patient with depression to thereby treat the depression, wherein the one or more nerves are selected from the group consisting of:

supra orbital nerve, supra trochlear nerve, lacrimal nerves, infratrochlear nerve, external nasal branch of anterior ethmoidal nerve, and mixtures thereof.

2. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.

3. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type B.

4. The method of claim 1, wherein the botulinum toxin is administered by injection.

5. The method of claim 1, wherein the botulinum toxin is administered to the nerve endings.

6. A method for treating depression comprising directly administering a botulinum toxin to one or more nerves of a patient with depression to thereby treat the depression, wherein the one or more nerves are selected from the group consisting of:

infraorbital nerve, zygomaticofacial nerve, zygomaticotemporal nerve, and mixtures thereof.

7. The method of claim 6, wherein the botulinum toxin is a botulinum toxin type A.

8. The method of claim 6, wherein the botulinum toxin is a botulinum toxin type B.

9. The method of claim 6, wherein the botulinum toxin is administered by injection.

10. The method of claim 6, wherein the botulinum toxin is administered to the nerve endings.

11. A method for treating depression comprising directly administering a botulinum toxin to one or more nerves of a patient with depression to thereby treat the depression, wherein the one or more nerves are selected from the group consisting of:

mental nerve, buccal nerve, auriculotemporal nerve, and mixtures thereof.

12. The method of claim 11, wherein the botulinum toxin is a botulinum toxin type A.

13. The method of claim 11, wherein the botulinum toxin is a botulinum toxin type B.

14. The method of claim 11, wherein the botulinum toxin is administered by injection.

15. The method of claim 11, wherein the botulinum toxin is administered to the nerve endings.